The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO WCGIC 2022 | TAS-102 plus bevacizumab vs. TAS-102 alone for previously treated metastatic esophagogastric cancer
Per Pfeiffer, MD, PhD, Odense University Hospital and University of Southern Denmark, Odense, Denmark, discusses an investigator-initiated randomised study that compared the combination therapy of TAS-102 (trifluridine–tipiracil) plus bevacizumab with TAS-102 alone in previously-treated patients with metastatic esophagogastric adenocarcinoma. 103 patients were enrolled in the trial. No significant difference was found between the two arms in terms of progression-free survival, overall survival, or adverse events, however, the data suggested that patients who were receiving the treatment as third-line or later benefitted from the addition of bevacizumab. This interview took place at the European Society for Medical Oncology World Congress on Gastrointestinal Cancer (ESMO WCGIC) 2022 in Barcelona, Spain.
